Yosuke Onishi

发表

Serum pentraxin 3 concentration correlates with disease severity in patients with myasthenia gravis

A. Uzawa, S. Kuwabara, T. Mizuno, 2022, Clinical Neurology and Neurosurgery.

Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome

A. Uzawa, S. Kuwabara, T. Mizuno, 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

Marked Respiratory Failure in an Ambulant Patient with Immune-mediated Necrotizing Myopathy and Anti-Kv1.4 and Anti-titin Antibodies

I. Nishino, Shigeaki Suzuki, S. Kuwabara, 2021, Internal medicine.

Japan MG registry: Chronological surveys over 10 years

Shigeaki Suzuki, A. Uzawa, M. Takahashi, 2022, Clinical and Experimental Neuroimmunology.

Role of soluble forms of follicular helper T-cell membrane molecules in the pathogenesis of myasthenia gravis

A. Uzawa, S. Kuwabara, Y. Kojima, 2023, Journal of Neuroimmunology.

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

J. Statland, M. Pasnoor, J. Verschuuren, 2021, The Lancet Neurology.

Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis

Shigeaki Suzuki, A. Uzawa, S. Kuwabara, 2023, Journal of Neurology, Neurosurgery, and Psychiatry.

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Denny J. Padgett, Adam L. Comer, Yi-Chung Lee, 2023, The Lancet Neurology.

Long-term outcomes and prognostic factors in generalized myasthenia gravis

A. Uzawa, S. Kuwabara, Y. Kojima, 2021, Journal of Neurology.

Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis

Shigeaki Suzuki, A. Uzawa, S. Kuwabara, 2023, Neurotherapeutics.

Minimal symptom expression achievement over time in generalized myasthenia gravis

A. Uzawa, S. Kuwabara, M. Yasuda, 2023, Acta Neurologica Belgica.

Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis

A. Uzawa, S. Kuwabara, Y. Kojima, 2021, Scandinavian journal of immunology.

Effects of BL 23 (Shenshu) acupuncture on serum cytokine levels in healthy adults: A randomized double-blind sham-controlled phase 1 study

A. Uzawa, S. Kuwabara, Yohei Kawasaki, 2023, Journal of Neuroimmunology.

Serum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase antibodies

A. Uzawa, M. Yasuda, Y. Ozawa, 2023, Journal of Neuroimmunology.

Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis

A. Uzawa, K. Utsugisawa, Y. Nagane, 2024, Annals of clinical and translational neurology.

Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan

Shigeaki Suzuki, A. Uzawa, K. Utsugisawa, 2023, Journal of Neuroimmunology.

Effects of Denosumab and Bisphosphonates on Glucocorticoid-induced Osteoporosis in Patients with Neuroimmunological Disorders.

M. Mori, A. Uzawa, M. Yasuda, 2024, Internal medicine.